OP could've worded it better, but that drug is under trials so the jury is still out on this one. Additional info from noema pharma's website: > Gemlapodect (NOE-105) is a potent, selective PDE10A inhibitor that safely modulates dopamine D2 receptor signaling in people with Childhood Onset Fluency Disorder (COFD, also known as Stuttering). > Increased D2 receptor signaling is suggested to contribute to both the learning and expression of tics, and D2 receptor antagonists (antipsychotics) are the only currently approved treatments for TS and there is no approved treatment for COFD. Gemlapodect (NOE-105) modulates the signaling instead of blocking it.